MDXGNASDAQHealthcare · Biotechnology

MiMedx Group, Inc.

$3.71+1.92%(+$0.07)

TickerSpark Score

78/100

Solid

Valuation

Profitability

Growth

100

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDXG research report →

52-Week Range14% of range

Low $3.03

Current $3.71

High $7.99

Companywww.mimedx.com

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

CEO: Joseph H. Capper
IPO: 2008
Employees: 837
HQ: Marietta, GA, US

Price Chart

-48.19% · this period

Valuation

Market Cap: $552.59M
P/E: 17.94
P/S: 1.42
P/B: 2.27
EV/EBITDA: 7.11
Div Yield: 0.00%

Profitability

Gross Margin: 81.04%
Op Margin: 10.17%
Net Margin: 7.88%
ROE: 12.86%
ROIC: 10.81%

Growth & Income

Revenue: $418.63M · 19.99%
Net Income: $48.58M · 14.52%
EPS: $0.33 · 13.79%
Op Income: $63.89M
FCF YoY: 13.11%

Performance & Tape

52W High: $7.99
52W Low: $3.03
50D MA: $3.80
200D MA: $5.85
Beta: 1.46
Avg Volume: 1.46M

Get TickerSpark's AI analysis on MDXG

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Mar 13, 26	Hulse William Frank IV	officer: General Counsel and CAO	other	20,245	$88.67K
Mar 13, 26	Maersk-Moller Kimberly	officer: Chief Commercial Officer	other	6,762	$29.62K
Mar 10, 26	Maersk-Moller Kimberly	officer: Chief Commercial Officer	other	42,845	$192.80K
Mar 10, 26	Maersk-Moller Kimberly	officer: Chief Commercial Officer	other	21,270	$95.72K
Mar 10, 26	Hulse William Frank IV	officer: General Counsel and CAO	other	136,364	$613.64K
Mar 10, 26	Hulse William Frank IV	officer: General Counsel and CAO	other	61,460	$276.57K
Mar 10, 26	DOUG RICE	officer: Chief Financial Officer	other	243,000	$1.09M
Mar 10, 26	DOUG RICE	officer: Chief Financial Officer	other	96,363	$433.63K
Mar 4, 26	Capper Joseph H	officer: Chief Executive Officer	other	310,574	$1.58M
Mar 4, 26	Capper Joseph H	officer: Chief Executive Officer	other	371,094	$0

Our MDXG Coverage

View all →

ipo_article

Conexeu Sciences Inc. IPO: What to Know Before It Lists

Conexeu Sciences Inc. (NASDAQ: CNXU) is expected to list on 2026-05-21, with the price range not yet disclosed. The setup is a preclinical regenerative medicine story with no FDA-cleared product yet, so shareholders should watch for pricing, dilution, and how the market values the pipeline risk.

May 20, 2026